Professional Advisory Board

Dewey McLin, PhD

Dewey McLin, PhD, served as Vice President, Medical Affairs for Longboard Pharmaceuticals (a wholly-owned subsidiary of Lundbeck), supporting the development of treatments for rare neurological conditions, including bexicaserin for the treatment of seizures associated with developmental and epileptic encephalopathies (DEEs).  

Prior to working on bexicaserin, Dewey was part of the Medical Affairs team at Greenwich Biosciences, helping launch Epidiolex (cannabidiol) for the treatment of seizures associated with Lennox-Gastaut syndrome, Dravet syndrome and tuberous sclerosis complex. 

He earned a doctorate degree and subsequently held an adjunct faculty position at the University of California, Irvine in Neurobiology and Behavior. Dr. McLin has held affiliate faculty positions at the University of California, San Diego, Chapman University, and the University of Texas at Austin College of Pharmacy.

Dewey has enthusiastically participated at the Epilepsy Awareness & Education Expo and Epilepsy Awareness Day at Disneyland for several years and looks forward to being part of its future!